A Phase 3 Study to Evaluate the Immunogenicity and Safety of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, in High-risk Adults
Clinical Trial Grant
Awarded By
Moderna Therapeutics, Inc.
Start Date
November 7, 2023
End Date
October 26, 2026
Awarded By
Moderna Therapeutics, Inc.
Start Date
November 7, 2023
End Date
October 26, 2026